CSLHAM:CSJ +2.20%73 PB Ratio is 2.11 as of Jun. 25, 2026, which is 83% below its 10-year median of 12.76. GuruFocus rates HAM:CSJ with a GF Score™ of 73/100 and a GF Value™ of €170.71 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,233 Biotechnology companies, CSL ranks better than 64.07% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-25), CSL's share price is €69.73. CSL's Book Value per Share for the quarter that ended in Dec. 2025 was €33.05. Hence, CSL's PB Ratio of today is 2.11.
The historical rank and industry rank for CSL's PB Ratio or its related term are showing as below:
HAM:CSJ'
s PB Ratio Range Over the Past 10 Years
Min: 1.58 Med: 12.76 Max: 21.51
Current: 2.04
During the past 13 years, CSL's highest PB Ratio was 21.51. The lowest was 1.58. And the median was 12.76.
HAM:CSJ's PB Ratio is ranked better than 64.07% of 1233
companies
in the Biotechnology industry
Industry Median: 2.83
vs HAM:CSJ: 2.04
During the past 12 months, CSL's average Book Value Per Share Growth Rate was 7.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 25.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 26.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CSL was 37.20% per year. The lowest was -8.90% per year. And the median was 13.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CSL PB Ratio Related Terms
CSL PB Ratio Historical Data
* Premium members only.
The historical data trend for CSL's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's PB Ratio distribution charts can be found below:
* The bar in red indicates where CSL's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
CSL's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CSL (HAM:CSJ) has a PB Ratio of 2.11 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CSL and its competitors. This is 83% below median its historical median of 12.76. Over the past decade, CSL's PB Ratio has ranged from 1.58 to 21.51. According to the industry distribution chart, CSL ranks #443 out of 1233 companies in the Biotechnology industry, placing it in the top 35.9%.
Is CSL's PB Ratio too high?
CSL's current PB Ratio of 2.11 is 83% below median its 10-year median of 12.76. Over the past 10 years, this metric has ranged from a low of 1.58 to a high of 21.51. The Biotechnology industry median PB Ratio is 2.83. CSL's value of 2.11 is 25.4% below this industry median. Based on the distribution chart, CSL ranks #443 out of 1233 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #443 out of 1233 companies for PB Ratio. This puts CSL in the upper half of its industry. The industry median PB Ratio is 2.83. CSL's value of 2.11 is 25.4% below this benchmark. Historically, CSL's own PB Ratio has ranged from 1.58 to 21.51 over the past decade. While the company's 10-year median is 12.76 vs. the industry median of 2.83, CSL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.83, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current PB Ratio of 2.11 is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CSL and its competitors. For the Biotechnology industry, the median PB Ratio is 2.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current PB Ratio is 2.11, which is 83% below median its own 10-year median of 12.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (HAM:CSJ) is currently considered Significantly Undervalued. The stock's GF Value™ is €170.71, compared to a current price of €69.73 — trading 59.2% below its estimated fair value. The current PB Ratio is 2.11, which is 83% below median its 10-year median of 12.76 and 25.4% below the Biotechnology industry median of 2.83. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CSL (HAM:CSJ), the current PB Ratio is 2.11 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (HAM:CSJ) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of €69.73 is trading 59.2% below its estimated GF Value™ of €170.71.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for HAM:CSJ:
PB Ratio: 2.11 (83% below median its 10-year median of 12.76)
GF Value™: €170.71 vs. price of €69.73 (59.2% below fair value)
Industry Position: 25.4% below the Biotechnology median (#443 of 1233)
No single metric tells the full story. See the HAM:CSJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for HAM:CSJ
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:CSJ has been successfully added to your 
